Navigation Links
Pulmo BioTech Inc. Announces Paper to be Presented at Symposium
Date:5/4/2009

NEW YORK, May 4 /PRNewswire-FirstCall/ -- Pulmo BioTech Inc. (OTC Bulletin Board: PLMO; Frankfort Borse: PLO) has announced that Dr. Jocelyn Dupuis, the Chief Scientific Officer of its Pulmo Science Inc. subsidiary and the originator of the PulmoBind concept is to present a paper at the 5th International Symposium on Peptide Receptors and Kinin 2009 to be held in Quebec, Canada from June 26th to 29th.

The paper, which is titled "Development of Radiolabeled Adrenomedullin Analogs Designed for Molecular Imaging of the Pulmonary Circulation", will be part of the session "From a Peptide to a Drug: Rational Drug Design".

This multidisciplinary and highly prestigious symposium aims to bring together outstanding scientists from around the world to discuss the most recent developments and future trends in basic and clinical research on a variety of peptides, neuropeptides and G-protein-coupled receptors (GPCR).

"We are very pleased that Dr. Dupuis has been chosen to present a paper on our Molecular Imaging technology at the Peptide Receptors International Symposium. As a company, Pulmo BioTech Inc. believes strongly in the peer review process and academic publishing, and we are delighted to have been given the opportunity to bring to an open forum some of the technical details of our development work." - Garry McCann, CEO Pulmo BioTech Inc.

About Pulmo BioTech Inc.

Pulmo BioTech Inc. specializes in the development and marketing of medical technology and research. Our proven strengths combine extensive commercial experience and academic credentials. The principal staff members are acknowledged experts in their specialized fields, and work with a broad range of investment institutions. Our mission is to utilize scientific imagination and drive, together with managerial and financial acumen, to bring innovative and profitable products to the marketplace to the benefit of all stock holders.

About PulmoScience Inc.

PulmoScience Inc. was established in 2006, and is currently developing a non-invasive Molecular Imaging technique for the diagnosis of Pulmonary Embolism, Pulmonary Hypertension and Lung Inflammatory diseases under the trade name PulmoBind.

PulmoScience was conceived within the Montreal Heart Institute "MHI" (a world renowned hospital and educational facility). Jointly owned by MHI subsidiary Innovacor as the technical and operational partner, Dr. Jocelyn Dupuis (the scientific director and originator of the PulmoBind Molecular Imaging technology), and by Pulmo BioTech Inc. as the funding partner, PulmoScience Inc. aims to develop this unique and exciting technology, to fund necessary trials, and to bring the products to market.

PulmoScience believes that the market for its product candidates is worth in excess of $500 million per annum and that, provided Regulatory Approval is achieved, the safety and efficacy of its products could allow it to dominate that market.

About PulmoBind

PulmoBind uses an intravenously delivered radionuclide tagged molecule which specifically bonds to the inner walls of the circulatory system in the lungs, and by the use of an external Gamma Camera allows an image of the integrity of the blood vessels throughout the lungs to be seen by a diagnostic clinician. PulmoScience is currently undertaking Regulatory Approval for Phase I Human Trials, and while subsequent results from additional tests might not corroborate the current results, PulmoScience believes that PulmoBind has the potential to dominate the market for the diagnosis of Pulmonary Embolism. In particular, this belief is driven by PulmoScience's expectations of the improved safety and efficacy that PulmoBind will offer when compared to the current incumbent nuclear medicine based technology for the diagnosis of Pulmonary Embolism. In addition, early indications are that PulmoBind could be highly effective in the early stage diagnosis of Pulmonary Hypertension, a condition for which there is no current front line diagnostic test. The addressable market for the product candidates being developed by PulmoScience is believed by the company to be worth in excess of $500 million per annum.

Further Information

For further information regarding Pulmo BioTech Inc. or PulmoScience, please visit www.pulmobiotech.com.

Forward-Looking Statements

Forward-looking statements contained in this and other written and oral reports are made based on known events and circumstances at the time of release, and as such, are subject in the future to unforeseen uncertainties and risks. All statements regarding future performance, earnings projections, regulatory approval, events or developments are forward-looking statements. It is possible that the future performance of the company may differ materially from current expectations, depending on economic conditions and the uncertainty of regulatory approval. A change in economic conditions may have a particularly volatile effect on results. Among the other factors which may affect future performance are: competitive market conditions and resulting effects on sales and pricing; increases in raw-material costs that cannot be recovered in product pricing; and global economic factors, including difficulties entering new markets and general economic conditions such as inflation, interest rates and credit availability. The company makes these statements as of the date of this disclosure, and undertakes no obligation to update them.

ISIN: US7458451074

CUSIP: 745845107


'/>"/>
SOURCE Pulmo BioTech Inc.
Copyright©2009 PR Newswire.
All rights reserved

Related biology technology :

1. FDA Approves SYMBICORT(R) for Chronic Obstructive Pulmonary Disease (COPD)
2. Nektar Announces Closing of Sale of Specific Pulmonary Delivery Assets to Novartis for $115 Million
3. Soliris(R) Reduced Measures of Thrombosis and Inflammation, and Decreased Indicators of Pulmonary Hypertension, in Studies of Patients with PNH
4. Nektar Sells Pulmonary Business to Novartis For $115 Million and Nektar Retains Key Pulmonary Programs Including Amikacin Inhale, Inhaled Vancomycin, and Ciprofloxacin Inhalation Powder
5. Pulmonary Hypertension Association Names Recipient of 2008 Award of Excellence in Pulmonary Arterial Hypertension (PAH) Care
6. Coalition for Pulmonary Fibrosis and American Thoracic Society Continue Research Partnership Through 2010
7. Pulmo BioTech Announces an Increase in its Stake in PulmoScience
8. Nektar Receives Patent Covering Pulmonary Targeted Antibiotics
9. Pulmo BioTech Announces Appointment of Chief Financial Officer
10. eResearchTechnology, Inc. and nSpire Health, Inc. Form Alliance to Deliver Integrated Cardiac Safety and Pulmonary Clinical Trial Services
11. CryoLife Announces Implant of First FDA-Cleared SynerGraft(R) Processed Human Pulmonary Heart Valve
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:9/20/2017)... (PRWEB) , ... September 20, 2017 , ... ... a collaboration with Koch Agronomic Services (Koch) to feature new innovations aimed at ... to broadcast first quarter 2018. American Farmer airs Tuesdays at 8:30aET on RFD-TV. ...
(Date:9/20/2017)... ... September 20, 2017 , ... Proscia Inc. ... , a provider of whole slide imaging solutions, are hosting a pre-conference workshop ... entitled “Successfully Deploying a Best-in-Class Strategy for Digital Pathology,” will feature Proscia CEO, ...
(Date:9/20/2017)... ... 20, 2017 , ... RoviSys, a leading independent provider of ... of an office in Taipei, Taiwan. This new location allows RoviSys to better ... relationships in the region. Located in the Neihu area of Taipei, the office ...
(Date:9/19/2017)... ... ... Biopharma ’s CEO and founder, Dr. Bob Harman DVM, MPVM, is featured in an interview ... Rising Tide". Dr. Harman and Dr. Riordan met in 2003 and have remained in ... of stem cell therapy and a fast friendship was formed. , Dr. Harman has been ...
Breaking Biology Technology:
(Date:6/14/2017)... IBM ) is introducing several innovative partner startups at ... between startups and global businesses, taking place in ... startups will showcase the solutions they have built with IBM ... France is one of the most ... increase in the number of startups created between 2012 and ...
(Date:5/16/2017)... 2017  Veratad Technologies, LLC ( www.veratad.com ), an ... identity verification solutions, announced today they will participate as ... 15 thru May 17, 2017, in Washington ... Center. Identity impacts the lives of ... quickly evolving digital world, defining identity is critical to ...
(Date:5/6/2017)... -- RAM Group , Singaporean based technology ... biometric authentication based on a novel  quantum-state ... perform biometric authentication. These new sensors are based on a ... Group and its partners. This sensor will have widespread ... security. Ram Group is a next generation sensor ...
Breaking Biology News(10 mins):